ProQR Therapeutics N.V. PRQR 深 滬
已收盤 02-06 16:00:00 美东时间
1.50
+0.040
+2.74%
華盛通- 最 高1.5197
- 今 開1.45
- 成交量 35.74万股
- 最 低 1.43
- 昨 收 1.46
- 總市值 1.58亿
- 52周最高 3.10
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 1.07
- 委 比 -57.63%
- 總股本 1.05亿
- 歷史最高 27.60
- 量 比 0.77
- 振 幅 6.14%
- 歷史最低 0.53
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
ProQR Therapeutics reported progress in advancing its pipeline programs, including positive early safety and pharmacokinetic data for AX-0810 and selection of development candidates for AX-2402 and AX-2911. Strategic collaboration milestones with Eli Lilly further strengthened the company’s financial position.
01-08 13:00
ProQR to Participate in 8th Annual Evercore Healthcare Conference
ProQR Therapeutics will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025. The company highlights its Axiomer™ RNA editing technology, which uses ADAR to make precise RNA edits, potentially treating diseases caused by RNA mutations. ProQR focuses on developing RNA therapies for rare and prevalent diseases. Webcast details are available on their website, and an archive will be accessible for 30 day...
2025-12-01 13:00
ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.
2025-11-06 20:16
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
2025-11-04 21:26
ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases
ProQR ( ($PRQR) ) has issued an announcement. On November 3, 2025, ProQR Therap...
2025-11-04 05:27
ProQR Therapeutics Gets European Medicines Agency's Committee's Authorization For Clinical Trial Application For Phase 1 Trial Of AX-0810 To Treat Clerosing Cholangitis, Biliary Atresia
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that
2025-10-20 20:12
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
ProQR Therapeutics has received approval for its AX-0810 Clinical Trial Application, enabling the initiation of a Phase 1 study in healthy volunteers to assess safety, tolerability, pharmacokinetics, and target engagement. AX-0810, an RNA editing oligonucleotide targeting NTCP, aims to treat cholestatic diseases like primary sclerosing cholangitis. TheCompany will host an investor event on November 3, 2025, to discuss the trial and its implicatio...
2025-10-20 12:00
ProQR to Participate in Upcoming Investor Conferences in October 2025
ProQR Therapeutics, specializing in RNA therapies using its Axiomer RNA editing platform, announces its participation in three upcoming investor conferences: the H.C. Wainwright Genetic Medicines Virtual Conference (Oct 14-15), H.C. Wainwright Liver Disease Virtual Conference (Oct 21-22), and Chardan’s 9th Annual Genetic Medicines Conference (Oct 21). The company will present its RNA editing technology, which uses ADAR to correct RNA mutations, p...
2025-10-13 12:30
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
2025-08-08 20:16
